Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
Mayo Clinic
Wake Forest University Health Sciences
University of Alabama at Birmingham
Roswell Park Cancer Institute
Weill Medical College of Cornell University
Hackensack Meridian Health
Celgene
Dana-Farber Cancer Institute
Mayo Clinic
Dana-Farber Cancer Institute
Hoffmann-La Roche
AbbVie
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
University of Southern California
GlaxoSmithKline
GlaxoSmithKline
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
Otsuka Pharmaceutical Co., Ltd.
Celgene
University of California, Davis
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
St. Petersburg State Pavlov Medical University
Wuerzburg University Hospital
CARsgen Therapeutics Co., Ltd.
Hellenic Society of Hematology
Sorrento Therapeutics, Inc.